Top Stock Reports for Eli Lilly, Danaher & Citigroup
https://www.zacks.com/commentary/2220146/top-stock-reports-for-eli-lilly-danaher-citigroup?cid=CS-ZC-FT-research_daily-2220146
Feb 02, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).
0
Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes
https://www.cnbc.com/2024/02/06/healthy-returns-novo-nordisk-eli-lilly-tackle-weight-loss-drug-supply-woes.html
Feb 06, 2024 - Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
0
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
https://www.cnbc.com/2024/02/06/eli-lilly-weight-loss-drug-may-treat-fatty-liver-disease.html
Feb 06, 2024 - The results add to a long list of potential health benefits of tirzepatide besides helping patients shed significant pounds and regulate blood sugar.
0
Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy
https://seekingalpha.com/news/4063338-nash-drug-developers-drop-trial-win-lilly-drug?source=feed_sector_healthcare
Feb 06, 2024 - Companies focused on NASH drugs drop as Eli Lilly's (LLY) weight loss drug, tirzepatide, hits main goal in a mid-stage trial for the liver disease. Read more here.
0
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
https://www.zacks.com/stock/news/2222669/etfs-to-buy-as-mounjaro-powers-eli-lilly-s-q4-earnings-beat?cid=CS-ZC-FT-etf_news_and_commentary-2222669
Feb 07, 2024 - Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
0
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
https://www.cnbc.com/2024/02/10/weight-loss-drugs-novo-nordisk-eli-lilly-are-tackling-supply-issues.html
Feb 10, 2024 - Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
0
4 stocks to watch on Friday: Plug Power, Eli Lilly and more
https://seekingalpha.com/news/4074559-4-stocks-to-watch-on-friday-plug-power-eli-lilly-and-more?source=feed_sector_healthcare
Mar 01, 2024 - Plug Power (PLUG), Eli Lilly (LLY), Microsoft (MSFT) and Warner Bros. Discovery (WBD) are the stocks to watch on Friday.
0
Eli Lilly said to have tapped National Resilience, BSP for Zepbound production
https://seekingalpha.com/news/4076137-eli-lilly-taps-national-resilience-bsp-make-zepbound?source=feed_sector_healthcare
Mar 05, 2024 - Eli Lilly (LLY) has inked deals with contract manufacturers National Resilience and BSP Pharmaceuticals to produce its weight loss drug Zepbound. Read more here.
0
Eli Lilly Zepbound prescriptions exceed Novo’s Wegovy for the first time in U.S.
https://seekingalpha.com/news/4080150-eli-lilly-zepbound-prescriptions-exceed-novos-wegovy?source=feed_sector_healthcare
Mar 15, 2024 - Eli Lilly's (LLY) weight loss drug Zepbound surpasses Novo Nordisk's (NVO) rival therapy Wegovy in terms of new US prescriptions for the first time. Read more here.
0
2seventy bio appoints Eli Casdin and Charles Newton to its board of directors
https://seekingalpha.com/news/4081841-2seventy-bio-appoints-eli-casdin-and-charles-newton-to-its-board-of-directors?source=feed_sector_healthcare
Mar 20, 2024 - 2seventy bio (TSVT) announces the appointment of Eli Casdin and Charles Newton to its board of directors.
0
Page 1>